CDKL5 (STK9) Antibody (C-term) Blocking peptide
€363.00
In stock
SKU
AC-BP7244b
Background:
Defects in STK9, a dual-specificity serine/threonine kinase, are a cause of atypical Rett syndrome. Rett syndrome is an X-linked dominant disease. It is a progressive neurologic developmental disorder and one of the most common causes of mental retardation in females. Patients appear to develop normally until 6 to 18 months of age, then gradually lose speech and purposeful hand movements and develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation, and stereotypic hand movements. After initial regression, the condition stabilizes and patients usually survive into adulthood. Rett syndrome due to CDKL5-associated mutations is characterized by a severe early-onset phenotype and atypical features such as infantile spasms.
Other Names:
Cyclin-dependent kinase-like 5, Serine/threonine-protein kinase 9, CDKL5, STK9
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7244b was selected from the C-term region of human STK9 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CDKL5 (HGNC:11411)
Gene ID: 6792
Primary Accession: O76039
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Defects in STK9, a dual-specificity serine/threonine kinase, are a cause of atypical Rett syndrome. Rett syndrome is an X-linked dominant disease. It is a progressive neurologic developmental disorder and one of the most common causes of mental retardation in females. Patients appear to develop normally until 6 to 18 months of age, then gradually lose speech and purposeful hand movements and develop microcephaly, seizures, autism, ataxia, intermittent hyperventilation, and stereotypic hand movements. After initial regression, the condition stabilizes and patients usually survive into adulthood. Rett syndrome due to CDKL5-associated mutations is characterized by a severe early-onset phenotype and atypical features such as infantile spasms.
Other Names:
Cyclin-dependent kinase-like 5, Serine/threonine-protein kinase 9, CDKL5, STK9
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7244b was selected from the C-term region of human STK9 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CDKL5 (HGNC:11411)
Gene ID: 6792
Primary Accession: O76039
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review